West-Nile encephalitis
diseaseOn this page
Also known as West Nile EncephalitisWest Nile fever with encephalitisWest Nile virus caused infectious encephalitisWest Nile virus infectious encephalitisWest-Nile fever
Summary
West-Nile encephalitis (MONDO:0019376) is a disease and 9 clinical trials. Top therapeutic interventions include sodium chloride and mgawn1. A subtype of West Nile fever — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (United States) [Orphanet-validated]
- Clinical trials: 9
Clinical features
Epidemiology
Prevalence records
8 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | 0.036 | Europe | Validated |
| Annual incidence | <1 / 1 000 000 | 0.02 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.17 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.66 | Greece | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | Hungary | Validated |
| Annual incidence | <1 / 1 000 000 | 0.07 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.12 | Romania | Validated |
| Point prevalence | 1-9 / 1 000 000 | 0.92 | United States | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | West-Nile encephalitis |
| Mondo ID | MONDO:0019376 |
| EFO | EFO:0007545 |
| Orphanet | 83476 |
| DOID | DOID:2365 |
| ICD-10-CM | A92.31 |
| SNOMED CT | 392662004 |
| UMLS | C0751583 |
| MedGen | 155889 |
| GARD | 0009959 |
| NORD | 1847 |
| Is cancer (heuristic) | no |
Also known as: West Nile Encephalitis · West Nile encephalitis · West Nile fever with encephalitis · West Nile virus caused infectious encephalitis · West Nile virus infectious encephalitis · West-Nile fever
Disease family
This is a subtype of West Nile fever. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › West Nile fever › West-Nile encephalitis
Subtypes (1): Kunjin virus infectous disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1 | 4 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07094724 | PHASE2 | RECRUITING | High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients |
| NCT00442169 | PHASE2 | COMPLETED | Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
| NCT00746798 | PHASE2 | COMPLETED | Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults |
| NCT00927953 | PHASE2 | TERMINATED | Treatment of West Nile Virus With MGAWN1 |
| NCT00091845 | PHASE1 | TERMINATED | An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease |
| NCT00106769 | PHASE1 | COMPLETED | Vaccine to Prevent West Nile Virus Disease |
| NCT00300417 | PHASE1 | COMPLETED | Phase I Study of West Nile Virus Vaccine |
| NCT00537147 | PHASE1 | COMPLETED | Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults |
| NCT04371003 | Not specified | WITHDRAWN | Prospective Investigation of Oxidative Stress in West Nile Virus Infection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SODIUM CHLORIDE | 4 | 1 |
| MGAWN1 | 2 | 1 |
Related Atlas pages
- Drugs: Sodium Chloride